NASDAQ:BIIB Biogen (BIIB) Stock Price, News & Analysis $251.95 -0.31 (-0.12%) As of 01:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biogen Stock (NASDAQ:BIIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biogen alerts:Sign Up Key Stats Today's Range$248.46▼$252.2350-Day Range$209.15▼$253.8452-Week Range$138.00▼$254.41Volume354,071 shsAverage Volume1.21 million shsMarket Capitalization$37.23 billionP/E Ratio44.59Dividend YieldN/APrice Target$241.89Consensus RatingModerate Buy Company Overview Biogen Inc. is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions. The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company serves patients and healthcare providers in markets around the world through its research, manufacturing and commercial operations. Christopher Viehbacher has served as Biogen’s president and chief executive officer since 2023.AI Generated. May Contain Errors. Read More Biogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreBIIB MarketRank™: 2.99379123011 of 5 starsBiogen scored higher than 60% of companies evaluated by MarketBeat, and ranked 447th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingBiogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 19 buy ratings, 11 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Biogen is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBiogen has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biogen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth30.84% Earnings GrowthEarnings for Biogen are expected to grow by 30.84% in the coming year, from $12.29 to $16.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biogen is 44.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Biogen is 44.15, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.56.Price to Earnings Growth RatioBiogen has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBiogen has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biogen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.73% of the float of Biogen has been sold short.Short Interest Ratio / Days to CoverBiogen has a short interest ratio ("days to cover") of 4.39.Change versus previous monthShort interest in Biogen has recently decreased by 7.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiogen does not currently pay a dividend.Dividend GrowthBiogen does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.04 News SentimentBiogen has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Biogen this week, compared to 11 articles on an average week.Search InterestOnly 14 people have searched for BIIB on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat Follows4 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biogen insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Biogen is held by insiders.Percentage Held by Institutions87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biogen's insider trading history. Receive BIIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Stock News HeadlinesBiogen earnings: what to look for from BIIB4 hours ago | finance.yahoo.comBiogen earnings: What to look for from BIIBOctober 27 at 3:42 AM | msn.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 27 at 1:00 AM | Profits Run (Ad)Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?October 26 at 12:36 PM | finance.yahoo.comBank of America Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) StockOctober 24 at 1:54 AM | americanbankingnews.comBiogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?October 23, 2026 | finance.yahoo.comWedbush Remains a Hold on Biogen (BIIB)October 22, 2026 | theglobeandmail.comContrasting Biogen (NASDAQ:BIIB) & Soligenix (NASDAQ:SNGX)October 22, 2026 | americanbankingnews.comSee More Headlines BIIB Stock Analysis - Frequently Asked Questions How have BIIB shares performed this year? Biogen's stock was trading at $175.99 at the beginning of the year. Since then, BIIB stock has increased by 41.9% and is now trading at $249.6940. How were Biogen's earnings last quarter? Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen's quarterly revenue was up 3.4% compared to the same quarter last year. Read the conference call transcript. Does Biogen have any subsidiaries? Biogen subsidiaries include Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and others. Who are Biogen's major shareholders? Biogen's top institutional investors include Robeco Institutional Asset Management B.V. (0.44%), Sumitomo Mitsui DS Asset Management Company Ltd (0.23%), Yousif Capital Management LLC (0.18%) and State of Alaska Department of Revenue (0.17%). Insiders that own company stock include Eric K Rowinsky, Nicole Murphy, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Priya Singhal and Rachid Izzar. View institutional ownership trends. How do I buy shares of Biogen? Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD), Alibaba Group (BABA), Bristol Myers Squibb (BMY) and Micron Technology (MU). Company Calendar Last Earnings7/29/2026Today10/27/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIIB's financial health is in the Green zone, according to TradeSmith. BIIB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BIIB CIK875045 Webwww.biogen.com Phone(617) 679-2000Fax617-679-2617Employees7,500Year Founded1978Price Target and Rating Average Price Target for Biogen$241.89 High Price Target$310.00 Low Price Target$175.00 Potential Upside/Downside-4.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage32 Analysts Profitability EPS (Trailing Twelve Months)$5.65 Trailing P/E Ratio44.66 Forward P/E Ratio20.51 P/E Growth2.99Net Income$1.29 billion Net Margins8.32% Pretax Margin10.09% Return on Equity11.18% Return on Assets6.88% Debt Debt-to-Equity Ratio0.39 Current Ratio1.87 Quick Ratio1.26 Sales & Book Value Annual Sales$9.89 billion Price / Sales3.77 Cash Flow$22.75 per share Price / Cash Flow11.08 Book Value$124.45 per share Price / Book2.03Miscellaneous Outstanding Shares147,750,000Free Float147,385,000Market Cap$37.25 billion OptionableOptionable Beta0.09 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BIIB) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
